TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of “Moderate Buy” by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $171.44.

TMDX has been the topic of several research reports. Canaccord Genuity Group raised their price objective on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Stephens raised their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Cantor Fitzgerald began coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective for the company. Needham & Company LLC assumed coverage on shares of TransMedics Group in a research report on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price on the stock. Finally, Oppenheimer lifted their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st.

Insider Buying and Selling

In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total value of $652,785.80. Following the transaction, the insider now directly owns 8,893 shares of the company’s stock, valued at approximately $1,353,514.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Anil P. Ranganath sold 4,289 shares of TransMedics Group stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total value of $652,785.80. Following the sale, the insider now owns 8,893 shares of the company’s stock, valued at $1,353,514.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,267,557.11. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,650,880 over the last three months. 7.00% of the stock is currently owned by company insiders.

Institutional Trading of TransMedics Group

A number of institutional investors have recently modified their holdings of TMDX. Sanctuary Advisors LLC acquired a new stake in TransMedics Group in the second quarter valued at $372,000. Teachers Retirement System of The State of Kentucky purchased a new position in shares of TransMedics Group in the 2nd quarter valued at about $420,000. NewEdge Advisors LLC lifted its stake in shares of TransMedics Group by 26.0% in the second quarter. NewEdge Advisors LLC now owns 10,372 shares of the company’s stock valued at $1,562,000 after purchasing an additional 2,140 shares during the period. Creative Planning boosted its holdings in TransMedics Group by 78.3% during the second quarter. Creative Planning now owns 9,173 shares of the company’s stock worth $1,382,000 after buying an additional 4,027 shares in the last quarter. Finally, Algert Global LLC acquired a new position in TransMedics Group during the second quarter worth about $2,685,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Price Performance

TMDX stock opened at $165.00 on Friday. The stock has a market cap of $5.43 billion, a price-to-earnings ratio of -485.29 and a beta of 1.99. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The business has a 50 day moving average price of $155.65 and a 200 day moving average price of $129.31.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company’s revenue for the quarter was up 117.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.03) EPS. Equities research analysts anticipate that TransMedics Group will post 1.23 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.